These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30203666)

  • 1. Pharmacotherapy-Induced Hepatitis B Reactivation Among Patients With Prior Functional Cure: A Systematic Review.
    Bath RM; Doering BE; Nailor MD; Goodlet KJ
    Ann Pharmacother; 2019 Mar; 53(3):294-310. PubMed ID: 30203666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: Data from a national US cohort.
    Serper M; Forde KA; Kaplan DE
    J Viral Hepat; 2018 Feb; 25(2):187-197. PubMed ID: 28845882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Biologics Treatment.
    Chen MH; Chen MH; Liu CY; Tsai CY; Huang DF; Lin HY; Lee MH; Huang YH
    J Infect Dis; 2017 Feb; 215(4):566-573. PubMed ID: 28011918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of anti-HBs in hepatitis B reactivation during direct-acting antiviral therapy for chronic hepatitis C.
    Spaan M; Bruce M; Agarwal K; Carey I
    Antivir Ther; 2018; 23(6):539-542. PubMed ID: 30309997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short article: Safety of targeted prophylaxis strategy in patients with resolved hepatitis B virus infection receiving rituximab for immune-mediated diseases.
    Spinicci M; Emmi G; Dies L; Barilaro A; Vitiello G; Mencarini J; Cavallo A; Bartoloni A; Bartalesi F
    Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):756-760. PubMed ID: 29649073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to hepatitis B screening and prophylactic lamivudine for prevention of rituximab-associated hepatitis B reactivation.
    Liu CY; Chandrasekar PH; Masood A; Schiffer CA
    J Oncol Pharm Pract; 2013 Mar; 19(1):18-23. PubMed ID: 22635416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV.
    Ogawa E; Furusyo N; Murata M; Toyoda K; Hayashi T; Ura K
    Liver Int; 2018 Jan; 38(1):76-83. PubMed ID: 28618152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virological Factors Associated With the Occurrence of Hepatitis B Virus (HBV) Reactivation in Patients With Resolved HBV Infection Analyzed Through Ultradeep Sequencing.
    Sakamoto K; Umemura T; Ito K; Okumura A; Joshita S; Ota M; Sugiyama M; Mizokami M; Yoneda M; Tanaka E
    J Infect Dis; 2020 Jan; 221(3):400-407. PubMed ID: 31550370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies.
    Smalls DJ; Kiger RE; Norris LB; Bennett CL; Love BL
    Pharmacotherapy; 2019 Dec; 39(12):1190-1203. PubMed ID: 31596963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: A cohort study from Egypt and meta-analysis of published data.
    El Kassas M; Shimakawa Y; Ali-Eldin Z; Funk AL; Wifi MN; Zaky S; El-Raey F; Esmat G; Fontanet A
    Liver Int; 2018 Dec; 38(12):2159-2169. PubMed ID: 29738637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HBsAg-negative/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation?
    Drößler L; Lehmann C; Töpelt K; Nierhoff D; Vehreschild JJ; Rybniker J; Hallek M; Fischer J; Stormberg V; Fätkenheuer G; Wieland U; Jung N
    Infection; 2019 Apr; 47(2):293-300. PubMed ID: 30689161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
    Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
    J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review.
    Gentile G; Antonelli G
    Viruses; 2019 Nov; 11(11):. PubMed ID: 31717647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactivation of resolved hepatitis B virus infection combined with nephrotic syndrome in a patient after allogeneic haematopoietic stem cell transplantation.
    Zhang JW; Zhang XZ; Sun YL; Long B; Wang XZ; Li XD
    BMC Infect Dis; 2019 Jan; 19(1):57. PubMed ID: 30651070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylaxis against hepatitis B reactivation among patients with lymphoma receiving rituximab.
    Buensalido JA; Chandrasekar PH
    Expert Rev Anti Infect Ther; 2014 Feb; 12(2):151-4. PubMed ID: 24341369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals.
    Belperio PS; Shahoumian TA; Mole LA; Backus LI
    Hepatology; 2017 Jul; 66(1):27-36. PubMed ID: 28240789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
    Lee YH; Bae SC; Song GG
    Int J Rheum Dis; 2013 Oct; 16(5):527-31. PubMed ID: 24164839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Hepatitis B Reactivation Among Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors.
    Atteya A; Ahmad A; Daghstani D; Mushtaq K; Yassin MA
    Cancer Control; 2020; 27(1):1073274820976594. PubMed ID: 33297765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of HBV reactivation in non-oncological patients.
    Pisaturo M; Di Caprio G; Calò F; Portunato F; Martini S; Coppola N
    Expert Rev Anti Infect Ther; 2018 Aug; 16(8):611-624. PubMed ID: 30058401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.